Merck, Hanmi sign $870M deal for NASH drug Posted on August 4, 2020 by Nile Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and commercialization milestones.